logo.jpg
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
March 25, 2021 16:06 ET | Processa Pharmaceuticals, Inc.
Clinical drug pipeline is funded and targeting major milestones in 2021 HANOVER, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"),...
logo.jpg
Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
March 22, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
logo.jpg
Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
March 17, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical...
Logo.png
Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement
March 02, 2021 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and...
Logo.png
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
January 11, 2021 10:50 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
Logo.png
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
November 05, 2020 09:15 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Logo.png
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
October 13, 2020 09:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, Md, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Logo.png
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
October 02, 2020 06:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA; Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that...
Logo.png
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS
August 20, 2020 09:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement with Yuhan Corporation, a South Korean...
Logo.png
PROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING
March 30, 2020 16:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, MD, March 30, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), announced the successful completion of their meeting with the U.S. Food and Drug Administration (FDA)...